Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05824520
Other study ID # 2023-0318
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 4, 2023
Est. completion date May 20, 2026

Study information

Verified date April 2023
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Jian'an Wang, MD
Phone +(86)(571) 87784808
Email wangjianan111@zju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall purpose of ACCURATE II trial is to compare the clinical outcomes of CT-derived FFR guided strategy versus medical therapy in patients with chronic coronary syndrome.


Description:

ACCURATE II is a prospective, multicenter, randomized clinical trial comparing the clinical outcome and cost-effectiveness of the two management strategies. CT-FFR-guided invasive treatment strategy versus optimal medical therapy, in management of patients with chronic coronary syndrome. The study is powered to detect if the primary endpoint by the CT-FFR-guided strategy is superior to the medical therapy strategy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1066
Est. completion date May 20, 2026
Est. primary completion date May 20, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years, with at least one vessel has CT-derived FFR=0.80 - Patients with chronic coronary syndromes - Signed written informed consent Exclusion Criteria: - The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Contrast media (Patients with documented sensitivity to contrast media which can be effectively pre-medicated with steroids and diphenhydramine [e.g. rash] may be enrolled) - Prior percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) - Sinus arrhythmia, cardiogenic shock, or severe heart failure (NYHA=III) - Inability or unwillingness to undergo CT scan or coronary angiography - Patients on hemodialysis or with severe hepatic or renal insufficiency - Left main coronary artery stenosis = 50% - Target vessel total occlusion - Pregnancy or intention to become pregnant during the course of the trial - Patients with a life expectancy less than 2 years

Study Design


Intervention

Other:
ITS plus OMT
Invasive treatment strategy plus optimal medical therapy
OMT
Optimal medical therapy alone

Locations

Country Name City State
China Second Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Major adverse cardiac events (MACE) A composite of all-cause death, myocardial infarction (MI) or ischemia-driven revascularization. 1 year
Secondary Death All-cause death and cardiac death. 1 year
Secondary MI Target vessel related and non-target vessel related MI. 1 year
Secondary Revascularization Ischemia driven, non-ischemia driven, target vessel and non-target vessel revascularization. 1 year
Secondary Stroke Stroke (ischemic and hemorrhagic). 1 year
Secondary Cost-effectiveness analysis Medical expenses of treatment and follow-up. 1 year
Secondary Quality of life assessed by Seattle Angina Questionnaire Frequency of angina and the disease-specific quality of life, as assessed by Seattle Angina Questionnaire. 1 year
Secondary MACE A composite of all-cause death, myocardial infarction (MI) or ischemia-driven revascularization. 1 month, 2 years, 3 years, 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A